SinoMab Bio­Science, Al­pham­ab On­col­o­gy make their way to the Hong Kong Stock Ex­change

While protests in Hong Kong are stretch­ing the lim­its of the re­gion’s econ­o­my, biotech­nol­o­gy com­pa­nies don’t ap­pear to be daunt­ed to list on the re­gion’s bourse.

Hong Kong-based SinoMab Bio­Science is look­ing to raise HK$1.75 bil­lion ($223 mil­lion) in a pub­lic of­fer­ing — while Souzou-based Al­pham­ab On­col­o­gy is gun­ning to raise up to $350 mil­lion in an IPO next month, ac­cord­ing to a Reuters re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER